InsiderTrades

Form 4 for SLDB Solid Biosciences Inc.

Accepted 2023-06-08 00:00:00 ET · period of report 2023-04-03 · accession 0000899243-23-014998 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2023-06-08 2023-04-03 SLDB SMITH IAN F Dir M - OptEx — +15.6K 53.2K +41% —
D 2023-06-08 2023-06-06 SLDB SMITH IAN F Dir A - Grant $0.00 +9,650 9,650 New $0
D 2023-06-08 2023-04-03 SLDB SMITH IAN F Dir M - OptEx $0.00 -15.6K 46.7K -25% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-04-03 M A 15,569 — 53,239 D — — (F1) Restricted stock units convert into common stock on a one-for-one basis.
2 Derivative Director Stock Option (Right to Buy) 2023-06-06 A A 9,650 $0.00 9,650 D $6.37 · — to 2033-06-06 9,650 Common Stock (F3) This option was granted on June 6, 2023 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.
3 Derivative Restricted Stock Units 2023-04-03 M D 15,569 $0.00 46,709 D — · — to — 15,569 Common Stock (F1) Restricted stock units convert into common stock on a one-for-one basis. (F2) The restricted stock units were granted on January 3, 2023 (the "Grant Date") and vest in equal quarterly installments beginning three months from the Grant Date, with the final installment vesting the date that is 12 months from the Grant Date; provided that in the event of the early termination of the First Amendment to Executive Chair Agreement between the Issuer and the reporting person (the "Smith Agreement") prior to the expiration of the Term (as defined in the Smith Agreement) and/or a change in control of the Issuer, the restricted stock units shall accelerate in full.